Raptor released positive phase 3 data for its Huntington's treatment in February, but since then little has happened. The share price is now depressed, presenting a good entry point.
U.S. stock futures were edging up going into Thursday's trading session, contradicting a soft European market and disappointing retail sales.
Imbruvica will be an important part of the treatment landscape for blood cancers.
U.S. stock futures were looking sunny this morning, building on a rise in the European markets.
Realogy is the best play on the improving housing market because it is leveraged operationally and financially to existing home sales, said Martin Sass, CEO of M.
The Israeli pharmaceutical maker may be considering a change of scene.
Shares of Exact Science Corp. (EXAS) surged on Tuesday after the FDA said it had approved the company's new colorectal screening product.
It's obvious DC-Vax came up futile in the early look at the phase III study data, leaving almost no chance the experimental cancer vaccine would benefit patients.
U.S. stock futures were rosy early Tuesday across the board, as investors assessed potential changes to the energy field with the Kinder Morgan reorganization foremost in mind.
Shoppers with subsidies buy 'silver' and those without buy 'bronze,' a study says. The subsidies seemed to add $75 per month in buying power.
Retropin employees were using alias Twitter accounts -- two of which affected the persona of gangster rappers -- to promote Retrophin and pitch short-sale recommendations of other stocks to followers.
U.S. stock futures were rising going into Monday, following a rocky week in the markets and despite continuing geopolitical instability.
For all the hype about Afrezza's greatness, Mann walks away with a joint venture in which he secures just one-third of Afrezza's potential profit -- and losses.
You may have never heard of Akorn, but investors in this pharmaceutical company have been richly rewarded in recent years.
The stock has fallen about 5% this week. The company's latest earnings report gives hints about whether the stock drop is just a blip.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV